Table 3.
Case | Pretreatment | Post‐treatment | |||
---|---|---|---|---|---|
CD56+ cell | CD56−CD3+ T cell | CD56+ cell | CD56−CD3+ T cell | ||
Microarray | #00 | 97.9 (80.9) | 97.5 | 97.5 (n.d.) | 93.7 |
#04 | 96.0 (33.7) | 99.4 | 95.0 (31.0) | 99.0 | |
#10 | 86.6 (51.5) | 88.4 | 99.1 (58.1) | 98.3 | |
#01 | 95.1 (95.6) | 99.2 | 97.7 (96.6) | 99.0 | |
#16 | 93.1 (91.1) | 95.6 | 93.0 (96.0) | 95.4 | |
#24 | 95.6 (59.7) | 98.6 | 95.1 (63.2) | 97.0 | |
Validation | #03 | 98.3 (86.0) | 98.9 | 97.0 (80.2) | 99.4 |
#05 | 95.3 (88.1) | 99.1 | 95.4 (91.9) | 99.5 | |
#08 | 95.1 (89.6) | 99.2 | 94.7 (81.9) | 99.5 | |
#13 | 97.3 (81.1) | 99.3 | 95.8 (90.5) | 99.5 | |
#25 | 97.5 (81.5) | 99.3 | 96.0 (96.3) | 99.2 | |
#12 | 95.4 (88.8) | 99.6 | 96.8 (90.5) | 98.7 | |
#22 | 95.1 (41.1) | 99.5 | 97.4 (34.1) | 99.8 | |
#23 | 98.2 (95.4) | 99.6 | 95.3 (60.7) | 98.9 |
The number in parenthesis represents the percentage of natural killer cells in CD56+ cells. n.d., not done.